Teva exercises Option to Invest in Andromeda Biotech
Yavne, Israel, June 17, 2010: Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. (“Andromeda”) at a company per-money valuation of 170 million US dollars.
Andromeda Biotech Initiates DIA-AID 2, a Confirmatory Phase 3 Study using DiaPep277®, for the Treatment of Type 1 Diabetes
Yavne, Israel, May 31, 2010: Andromeda Biotech Ltd. today announces the initiation of its’ confirmatory phase III clinical study, DIA-AID 2 using DiaPep277®, Andromeda’s lead product for the treatment of type 1 diabetes.
Andromeda Biotech Receives EMEA Support for the Clinical Development Plan of its Lead Product, DiaPep277, for the Treatment of Type 1 Diabetes
Yavne, Israel, November 23, 2009: Andromeda Biotech Ltd. announces that the European Medicines Agency, (EMEA), accepts the clinical development plan for DiaPep 277, Andromeda’s lead product for the treatment of type 1 diabetes.
Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for its Lead Drug, "DiaPep277" for Type 1 Diabetes
Yavne, Israel, September 8, 2009: Andromeda Biotech Ltd. (www.andromedabio.com) announced today that it has completed patient recruitment in its’ current Phase III study using DiaPep277 for the treatment of Type 1 diabetes.
Andromeda Biotech Consummates Deal with Teva for the Commercialization of DiaPep277, its Late Stage Development Drug for Type 1 Diabetes
Yavne, Israel, June 22, 2009: Andromeda Biotech Ltd. (www.andromedabio.com), announced today that Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has decided to exercise its option to complete a $13.5 million investment and license Andromeda’s DiaPep277 for the treatment of Type 1 diabetes. Pursuant to the agreements, Teva is receiving worldwide marketing rights for the DiaPep277 product.
Andromeda Biotech Announces Successful Phase III Interim Results of its Lead Product, DiaPep277 for the treatment of Type 1 Diabetes
Rehovot, Israel, December 29, 2008: Andromeda Biotech (www.andromedabio.com), a subsidiary of Clal Biotechnology Industries (CBI), focused on the development of innovative treatment for autoimmune diabetes announces positive results following the Phase III interim analysis for the company’s lead product, DiaPep277 for the treatment of Type 1 diabetes.
Andromeda Biotech announces Teva Pharmaceutical Industries’ decision to exercise their option and invest in the lead product, DiaPep 277, a late stage development drug for type 1 diabetes
Tel Aviv, Israel, August 19, 2008: Andromeda Biotech, a wholly owned subsidiary of Clal Biotechnology Industries Ltd. (CBI), focused on the development of innovative treatment for autoimmune diabetes, announced that Teva Pharmaceuticals decided to exercise their option and invest in Andromeda Biotech according to an amended agreement which was signed on August 17, 2008.
Andromeda Biotech Announces Successful Interim Results of Leading Product DiaPep 227 for Treatment of Type 1 Diabetes
Rehovot, Israel, June 23, 2008: Andromeda Biotech, a wholly owned subsidiary of CBI, focused on the development of innovative treatment for autoimmune diabetes, announced the successful results from the Interim Analysis of safety and efficacy data from the phase III clinical study conducted with DiaPep 277, the company's lead product for the treatment of type 1 diabetes.
DeveloGen and Andromeda, a newly formed wholly-owned subsidiary of Clal Biotechnology Industries, Complete Asset Purchase Agreement for the DiaPep277® Program
Goettingen, Germany/Tel-Aviv, Israel, June 14, 2007: DeveloGen Israel Limited (“DeveloGen”), a wholly owned subsidiary of DeveloGen AG, and Andromeda Biotech Ltd. ("Andromeda"), a newly formed wholly owned subsidiary of Clal Biotechnology Industries Ltd. ("CBI"), today announced that DeveloGen and Andromeda have completed the final agreement for an asset purchase agreement for DeveloGen's DiaPep277® program for the treatment of type 1 diabetes.
